Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis by Kane, Sunanda V. et al.
Prevalence of Nonadherence With Maintenance
Mesalamine in Quiescent Ulcerative Colitis
Sunanda V. Kane, M.D., M.S.P.H., Russell D. Cohen, M.D., James E. Aikens, Ph.D., and
Stephen B. Hanauer, M.D.
Department of Medicine, University of Chicago, Chicago, Illinois; and Department of Family Medicine,
University of Michigan, Ann Arbor, Michigan
OBJECTIVE: There are scant data regarding outpatient adher-
ence in quiescent ulcerative colitis aside from patients en-
rolled in controlled clinical trials. We conducted a preva-
lence study to determine the medication adherence rate of
maintenance therapy and to identify possible risk factors for
nonadherence.
METHODS: Outpatients with clinically quiescent ulcerative
colitis for 6 months on maintenance mesalamine (Asacol,
Procter and Gamble, Cincinnati, OH) were eligible. Patients
were interviewed regarding disease history, and demograph-
ics were obtained from medical records. Refill information
for at least 6 months was obtained from computerized phar-
macy records. Adherence was defined as at least 80% con-
sumption of supply dispensed. Using nonadherence as the
outcome of interest, stratified analysis and regression mod-
eling were used to identify significant associations.
RESULTS: Data were complete for the 94 patients recruited.
The overall adherence rate was found to be 40%. The
median amount of medication dispensed per patient was
71% (8–130%) of the prescribed regimen. Nonadherent
patients were more likely to be male (67% vs 52%, p 
0.05), single (68% vs 53%, p  0.04), and to have disease
limited to the left side of the colon versus pancolitis (83% vs
51%, p  0.01). Sixty-eight percent of patients who took
more than four prescription medications were found to be
nonadherent versus only 40% of those patients taking fewer
medications (p  0.05). Age, occupation, a family history of
inflammatory bowel disease, length of remission, quality-
of-life score, or method of recruitment (telephone interview
vs clinical visit) were not associated with nonadherence.
Logistic regression identified that a history of more than
four prescriptions (odds ratio [OR] 2.5 [1.4–5.7]) and male
gender (OR 2.06 [1.17–4.88]) increased the risk of nonad-
herence. Two statistically significant variables, which were
protective against nonadherence, were endoscopy within the
past 24 months (OR 0.96 [0.93–0.99]) and being married
(OR 0.46 [0.39–0.57]).
CONCLUSION: Nonadherence is associated with multiple
concomitant medications, male gender, and single status.
These patient characteristics may be helpful in targeting
those patients at higher risk for nonadherence. (Am J Gas-
troenterol 2001;96:2929–2933. © 2001 by Am. Coll. of
Gastroenterology)
INTRODUCTION
Ulcerative colitis (UC) is an idiopathic, chronic inflamma-
tory disease of the large intestine characterized by episodes
of relapse and remission. Relapses are often not predictable,
although factors such as smoking cessation (1, 2), chronic
nonsteroidal anti-inflammatory use (3, 4), and psychological
stress (5) are thought to cause symptom exacerbation in
some individuals.
Because of its chronic nature, therapy often must continue
on an indefinite basis. Multiple studies have demonstrated
the efficacy of aminosalicylates to induce and maintain
remission in UC (6–10). These well-designed, multicenter
trials have used pill count and patient inquiry to assess
adherence, with rates ranging from 70% to 95%. This
wide variance across studies can be explained by the study’s
definition of adherence, the degree to which the investiga-
tors were proactive in adherence measures, and patient pop-
ulation. Based upon community-based, follow-up studies in
other chronic illnesses, the percentage of long-term adher-
ence tends to be much lower, about 40–50% (11).
Despite the advances in treatment modalities, many pa-
tients experience relapses. Many patients openly admit they
do not take their medications as prescribed. Medication
taking probably makes patients more uncomfortably aware of
their chronic illness status. They have a fear of long-term side
effects from medications, and they question the need for med-
ication in the setting of quiescent disease. However, the impact
of medication adherence on specific inflammatory bowel dis-
ease (IBD) outcomes has not been fully explored. The purpose
of this point-prevalence study was first to determine the prev-
alence of adherence among patients taking mesalamine to
prevent relapse in quiescent UC, and then determine those risk
factors associated with nonadherent behavior.
MATERIALS AND METHODS
Patients
Consecutive patients were recruited from the Gastroenter-
ology Clinic at the University of Chicago from March to
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October, 1998. Potential patients were identified from three
sources: patient clinic visits, patient phone requests for
refills of Asacol, or pharmacy calls for Asacol. Those pa-
tients with a well-established diagnosis of UC confirmed by
endoscopy and histology were eligible. Entry criteria in-
cluded patients in clinical remission at least 6 months from
the time of potential recruitment. Remission was defined by
criteria modified from Truelove and Witts: one to three
formed bowel movements per day without bleeding, ur-
gency, or cramping (12). Patients also had to have docu-
mentation of Asacol use without concurrent oral or topical
steroids, or other immunomodulators such as azathioprine or
6-mercaptopurine to maintain remission. Exclusion criteria
included any evidence of clinically active disease in the
previous 6 months, no documented visit to a physician in
our clinic in the previous 18 months, or uncertainty of the
diagnosis (Crohn’s disease or indeterminate colitis).
Protocol
Retrospective data for each patient was collected during a
single interview. For patients recruited from pharmacy calls
to the office, refill data were obtained, and the medical
records verified the patient’s diagnosis. The patient was
called to confirm the refill and collect data on current clin-
ical status. For those patients who called the office to request
a refill, the pharmacy data were collected at the time of the
refill, the patient was contacted to confirm the refill and
obtain clinical information. For patients recruited from the
clinic, clinical data were collected during the patient inter-
view, the medical record reviewed for any missing infor-
mation, and then the pharmacy was contacted for refill data.
Demographic variables collected included age, gender,
marital status, occupation, and type of insurance. Disease
information included extent (proctitis, left-sided, pancolitis)
and duration of disease, length of present remission, me-
salamine dose and regimen, family history of IBD, and
concomitant medications. The length of time since last
steroid use, last hospitalization, and last colonoscopy were
also collected. A formal global assessment score including
patient well-being was not computed; however, quality of
life was measured using the Short Inflammatory Bowel
Disease Questionnaire (13). Data to compute this score were
obtained during the patient interview. To avoid acquisition
bias, all information was collected by one investigator
(S.V.K.), and information regarding clinical status was ob-
tained before and separate from MED-TOTAL calculations
(see below).
Statistical Analysis
Adherence was calculated using Steiner’s “MED-TOTAL”
formula, which has been validated in plasma drug levels
(phenytoin) and medical outcomes (diastolic blood pres-
sure) (14). Consumption of 80% of prescribed medica-
tions over a 6-month period was used as the definition of
“adherence.” We chose this percentage based on the prin-
ciple that loss of 20% of a patient population in a clinical
trial makes the results suspect and potentially invalid (15).
MED-TOTAL was calculated as:
Sum of days’ supply dispensed
Sum of days in all refill intervals
 100
The outcome variable of interest was adherence. 2 testing,
or McNemar’s test where appropriate, was performed to
compare frequencies of demographic variables and disease
characteristics between adherent versus nonadherent
groups. Multivariate logistic regression modeling was per-
formed to identify independent variables that correlated
with nonadherent behavior. Measurement of risk associated
with nonadherence using odds ratios (OR) was calculated
along with 95% CI. A p value of 0.05 was considered
statistically significant. All tests were two-tailed. The pro-
tocol was approved by the University of Chicago Institu-
tional Review Board before the collection of any data.
RESULTS
Ninety-four consecutive patients were enrolled in the co-
hort; their characteristics are shown in Table 1. The median
age was 42.5, 51% were men. Nearly half of the patients
(47%) had pancolitis with a median duration of disease of 8
yr. The median mesalamine dose was 3.9 g/day. Sixty-four
patients were recruited from the clinic, 20 from direct phar-
macy calls, and 10 via patient telephone refill requests.
We found that less than half of the patients (40%) were
adherent to their prescribed dose of mesalamine. The me-
dian amount of medication consumed was 71% (range
8–100) of the total prescribed dose.
There was a variety of dosing regimens used, but because
the majority of patients were taking b.i.d. mesalamine (67%
of the patients), dosing regimen was stratified as a dichot-
omous variable (b.i.d. vs other). Stratification by prescribed
dose or dosing regimen failed to reveal any significant
differences in adherence rates (Figs. 1 and 2). When strat-
ified by extent of disease, the trend toward nonadherence in
those with less extensive disease was significant at p  0.04.
Univariate analysis identified four factors, which were
significantly associated with nonadherence: male gender,
single status, a diagnosis of left-sided disease, and a history
of more than four concomitant medications. Logistic regres-




Age (yr) 42.5 (18–79)
Gender (% male) 51
Yr disease 8 (1–66)
Length remission (mo) 24 (6–360)
SIBDQ score 61 (45–70)
Dose (g/day) 3.88 (1.2–4.8)
Married (%) 53
Adherence (%) 40
SIBDQ  Short Inflammatory Bowel Disease Questionnaire.
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sion found that men were twice as likely to be nonadherent
than women (OR 2.1, 95% CI  1.2–4.8), and that a history
of more than four concomitant medications was associated
with a two and a half times increased chance of nonadher-
ence with mesalamine (OR 2.5, 95% CI  1.4–5.7). Con-
versely, being married, having had a recent colonoscopy,
and a greater extent of disease were all positively associated
with adherence (see Table 2).
DISCUSSION
We found when using objective pharmacy data, rather than
patient-derived information, the prevalence of medication
nonadherence was 60% in patients with quiescent UC. The
average amount of medication consumed was 70% of that
prescribed. These numbers are comparable with those seen
in asymptomatic phases of other chronic illnesses (11).
There are several published studies in the English litera-
ture addressing medication adherence in UC. van Hees and
van Tongeren (16) measured urine levels of acetylated sul-
fasalazine as a marker for adherence in 51 patients 1–6
months after hospital discharge and in 171 outpatients over
several years. The authors concluded that nonadherence, as
defined by undetectable urine levels, in the months after
hospital discharge approximated 41.2%. In 175 patients
followed on maintenance doses of sulfasalazine, 12% had
undetectable urine levels at 6-month follow-up.
In another study, Riley et al. included adherence as a
potential factor leading to disease relapse (17). Medication
adherence was determined by pill count and direct patient
inquiry. After 48 wk, there was no difference in adherence
rates between the group who relapsed versus those who
remained in remission. However, the total adherence for
both groups was 95% throughout the study, making the
interpretation of these findings difficult.
Because patients are implying consent to contact their
pharmacy for refills, we believed that this was the most
accurate reflection of medication consumption possible out-
side of a structured clinical trial. We assumed that the
number of pills dispensed to a patient over a certain time
interval was an accurate estimate of pill consumption. It is
believed that this assumption is valid because it is unlikely
that patients will pick up medications they have no intention
of taking. We collected data on at least 6 months’ worth of
medication refills. This would include at least two-time
intervals for those patients who are dispensed medications
for a 90-day period, and would minimize any bias associated
with a patient either “stockpiling” or self-medicating unbe-
knownst to the prescribing physician. It is also not the habit
of prescribing physicians at our institution to prescribe more
medication than deemed necessary to maintain remission to
ensure medication adherence.
There is no guarantee that our patients did not get med-
ications from several physicians. However, we tried to min-
imize this possibility by asking the pharmacist about all
prescriptions for mesalamine filled over the previous 6
months, regardless of physician name. In addition, all of the
pharmacies on record for each patient were contacted (i.e.,
the one close to work, the one close to home, etc.). In the
Chicago land area, the larger chains of commercial drug
stores are linked via a computer system, and so refills
obtained from multiple locations can be tracked.
Direct inquiry is a standard method for measuring adher-
ence, but for a variety of reasons patients are untruthful
when a physician asks patients if they are taking their
medication (18, 19). These include the fear of displeasing
their physician or shame or embarrassment regarding inabil-
ity to pay for medication. Pill counts for maintenance ther-
apy are cumbersome and do not necessarily reflect the true
medication consumption rates in outpatients.
One of the strengths of this study was the use of the Short
Inflammatory Bowel Disease Questionnaire to standardize
the severity of each patient’s perceived symptoms. Also,
there was no “nonresponder” bias as all eligible consecutive
patients were included. In addition, we tried to minimize any
Figure 2. Percent adherence by regimen. p  0.39. *27% three
times a day, 6% four times a day dosing.
Figure 1. Percent adherence by prescribed dose. p  0.53.
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selection bias by using several methods for patient recruit-
ment.
It is difficult to get patients to take medication when they
feel well, because the rationale for continued consumption is
unclear. The long-term goals of improving adherence are to
reduce frequency of relapse, lower the incidence of long-
term complications (i.e., colon cancer), and lower overall
health costs.
The consequences of nonadherence are self-evident in
other illnesses such as coronary heart disease and diabetes,
but not so for IBD. There are now several studies that
suggest that documented medication consumption is protec-
tive for colon cancer, which is an important concern for the
long-term natural history of UC. Moody et al. studied 168
patients with UC diagnosed between 1972 and 1981 and
correlated nonadherence with sulfasalazine with risk of
colorectal cancer (20). Their crude colectomy rate was 23%
in 10 yr with a 3% rate in those patients on maintenance
sulfasalazine, and 31% in patients either noncompliant or
off all medications. The study was a chart review, so non-
adherence was based on physician notation in the medical
record. The authors concluded that the 5-aminosalicylates
would also likely provide this same protection, but would
require further investigation.
Eaden et al. found in a separate case-control study that
mesalamine at a dose of 1.2 g/day reduced colorectal
cancer risk by 91% in patients with UC compared with no
treatment (21). There was also a protective effect of more
than two visits to the physician per year, but not for colonos-
copies.
In conclusion, in a tertiary care center where patients are
presumed to be more motivated and better educated regard-
ing their disease, we found a surprisingly low level of
medication adherence. From this study, we have shown that
men and nonmarried persons are at greatest risk for nonad-
herent behavior. As this was a prevalence study with the aim
to quantify and identify risk factors for medication nonad-
herence, no data on the consequences of nonadherent be-
havior was collected. Future prospective studies are war-
ranted to determine the effect of nonadherence on disease
course.
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